Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.68 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.68 |
| ▸ | DPP4 | P27487 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.68 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.68 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.68 |
| ▸ | GAPDH | P04406 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.68 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.68 |
| ▸ | STAT6 | P42226 | 1/20 | 0.68 |
| ▸ | PI4KA | P42356 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.68 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.68 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.68 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.68 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28991007 | 1.00 | ADORA3 (0.68) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL22333908 | 1.00 | ADORA3 (0.68) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL28569675 | 1.00 | ADORA3 (0.68) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL29498967 | 1.00 | ADORA3 (0.68) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL1061070 | 1.00 | ADORA3 (0.68) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL20138905 | 0.92 | ADORA3 (0.68) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL24371378 | 0.91 | ADORA3 (0.67) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL21999229 | 0.89 | AHCY (0.56) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL2227288 | 0.89 | ADORA1 (0.53) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL14916257 | 0.89 | ADORA1 (0.53) | ADORA3ADORA1DPP4MEN1SLC28A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188477-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDE HAVING RNAi ACTIVITY | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-06-12 | — | — | US | disclosed |
| US-20250188478-A1 | siRNA SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR 2 | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-06-12 | — | — | US | disclosed |
| WO-2025110249-A1 | COMPOSITION FOR NUCLEOTIDE SEQUENCE EDITING, AND NUCLEOTIDE SEQUENCE EDITING METHOD USING SAME | 国立大学法人 広島大学 | 2025-05-30 | — | — | WO | disclosed |
| WO-2025063238-A1 | SIRNA FOR SUPPRESSING EXPRESSION OF PHOSPHOLAMBAN | 第一三共株式会社 | 2025-03-27 | — | — | WO | disclosed |
| WO-2025063239-A1 | SIRNA CAPABLE OF SUPPRESSING EXPRESSION OF α-SYNUCLEIN | 第一三共株式会社 | 2025-03-27 | — | — | WO | disclosed |
| EP-4495241-A1 | CHEMICALLY-MODIFIED OLIGONUCLEOTIDE HAVING RNAI ACTIVITY | Daiichi Sankyo Company, Limited (JP) | 2025-01-22 | — | — | EP | disclosed |
| EP-4495240-A1 | SIRNA FOR SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR-2 | Daiichi Sankyo Company, Limited (JP) | 2025-01-22 | — | — | EP | disclosed |
| WO-2023176863-A1 | CHEMICALLY-MODIFIED OLIGONUCLEOTIDE HAVING RNAI ACTIVITY | 第一三共株式会社 | 2023-09-21 | — | — | WO | disclosed |
| WO-2023176862-A1 | siRNA FOR SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR-2 | 第一三共株式会社 | 2023-09-21 | — | — | WO | disclosed |
| US-20220378920-A1 | CONJUGATE OF GalNAc-OLIGONUCLEOTIDE FOR DELIVERY TO LIVER AND MANUFACTURING METHOD THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-12-01 | — | — | US | disclosed |
| US-20110009471-A1 | Oligonucleotide analogues and methods utilizing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-7816333-B2 | Oligonucleotide analogues and methods utilizing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-10-19 | — | — | US | disclosed |
| US-20090149404-A1 | Oligonucleotide analogues and methods utilizing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-06-11 | — | — | US | disclosed |
| US-7335765-B2 | Nucleoside and oligonucleotide analogues | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-02-26 | — | — | US | disclosed |
| US-7314923-B2 | Nucleoside and oligonucleotide analogues | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-01-01 | — | — | US | disclosed |
| US-20070270370-A1 | Novel bicyclonucleoside analogues | SANKYO COMPANY, LIMITED (JP) | 2007-11-22 | — | — | US | disclosed |
| US-7217805-B2 | Bicyclonucleoside analogues | SANKYO COMPANY, LIMITED (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20040143114-A1 | Novel bicyclonucleoside analogues | SANKYO COMPANY, LIMITED (JP) | 2004-07-22 | — | — | US | disclosed |
| US-20030207841-A1 | Novel nucleoside and oligonucleotide analogues | SANKYO COMPANY LIMITED (JP) | 2003-11-06 | — | — | US | disclosed |
| US-20020147332-A1 | Novel nucleoside and oligonucleotide analogues | SANKYO COMPANY, LIMITED (JP) | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270370-A1 | Novel bicyclonucleoside analogues | PURB, RNGTT, NSUN2 | ADORA3 294/4885ADORA1 177/4885DPP4 2018/4885 |
| US-20110009471-A1 | Oligonucleotide analogues and methods utilizing the same | NSUN2, RNGTT, DUT | ADORA3 316/4885ADORA1 198/4885DPP4 1105/4885 |
| US-20020147332-A1 | Novel nucleoside and oligonucleotide analogues | RNGTT, NSUN2, MTAP | ADORA3 58/4885ADORA1 35/4885DPP4 863/4885 |
| US-20090149404-A1 | Oligonucleotide analogues and methods utilizing the same | NSUN2, RNGTT, DUT | ADORA3 316/4885ADORA1 198/4885DPP4 1105/4885 |
| US-20250188478-A1 | siRNA SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR 2 | TFRC, FOLR2, FTH1 | ADORA3 3807/4885ADORA1 4046/4885DPP4 4471/4885 |
| US-20030207841-A1 | Novel nucleoside and oligonucleotide analogues | RNGTT, NSUN2, MTAP | ADORA3 58/4885ADORA1 35/4885DPP4 863/4885 |
| US-20220378920-A1 | CONJUGATE OF GalNAc-OLIGONUCLEOTIDE FOR DELIVERY TO LIVER AND MANUFACTURING METHOD THEREOF | CSGALNACT1, GALNT6, GALNT14 | ADORA3 1026/4885ADORA1 1345/4885DPP4 390/4885 |
| US-20040143114-A1 | Novel bicyclonucleoside analogues | PURB, DUT, NSUN2 | ADORA3 220/4885ADORA1 158/4885DPP4 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.